NCT04379739View on ClinicalTrials.gov

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

July 26, 2020

Primary Completion Date

June 29, 2022

Study Completion Date

December 30, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Camrelizumab

camrelizumab 200mg, q3w, i.v., 2-4 cycles;

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shang'ai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT04379739 - Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter